University of Strathclyde

Strathclyde is a leading, international, technological university based in the heart of Glasgow. It is renowned for its entrepreneurial environment and its success in commercialisation, being comfortably in the UK’s top 10 universities for company creation based on the ideas of its staff, students and alumni. The University’s commitment to innovation drives its investment activities. Mironid is the tenth company the University have invested in since 2012, reflecting its strategy of partnering with specialist lead investors, where its investment can make a real difference.

The Latest

Mironid raises $46 million in Series B financing to advance clinical development of its treatment for rare kidney diseaseAugust 5, 2026

Glasgow, Scotland, August 5, 2026 – Mironid, a biopharmaceutical company developing small molecule therapeutics for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD), a life-threatening hereditary kidney disease, today announces it has raised $46 million in a Series B funding round. Neil Wilkie, CEO of Mironid said: “ADPKD is the [...]

Mironid Raises Awareness for PKD with 1,000 km Team ChallengeApril 14, 2026

At Mironid, we’re proud to support causes that make a meaningful difference. Last month, our team took part in the Polycystic Kidney Disease (PKD) Charity UK‘s ‘Spring into March’ challenge, raising awareness and supporting the [...]

Q&A with David Henderson, Head of BiologyMarch 19, 2026

ADPKD is a devastating disease that affects more than 12 million people worldwide. Over the past decade, there has been important progress in our understanding of the disease, with meaningful steps forward for both patients and clinicians. However, significant challenges remain. Tolerability [...]